Skip to main content

New Electromedical Technologies Strategic Partner to Aid in Driving Awareness and Sales

Written by Customer Service on . Posted in Public Companies.

High profile firm WireBuzz boasts relationships with Fortune 500 firms and nation’s top health care companiesIndustry leading digital marketing agency renowned for driving awareness and online businessWireBuzz poised to aid Electromedical Technologies in onboarding new distributors and customers
SCOTTSDALE, Ariz., Dec. 07, 2020 (GLOBE NEWSWIRE) — Electromedical Technologies, Inc. (OTCQB: EMED ) (the “Company”), a pioneer in the development and manufacturing of bioelectronic devices, including the FDA cleared WellnessPro+, is pleased to announce its new strategic partnership with WireBuzz, LLC (www.wirebuzz.com), an award-winning video and web design agency. The Company elected to work with WireBuzz based upon its renowned reputation for content production, advanced marketing, and specifically, its impressive online customer conversion capabilities.In its first stage,  WireBuzz is revamping the Company website to emulate the style and success of sites for WireBuzz Fortune 500 clients, and others. Future steps include the production of new marketing tools including video content for use by Electromedical Technologies’ distributors and influencers. WireBuzz produces more than 3,000 videos each year, which are extremely powerful and effective visual sales resources. The use of online content marketing is one of the most successful sales methods in the current COVID-19 environment and is expected to be a major driver of product sales, going forward.In addition to its video marketing capabilities, WireBuzz also provides strategy and messaging development, sales process optimization and automation, and diverse content marketing campaigns.Matthew Wolfson, Founder and CEO of EMED, commented, “We are thrilled to be working with the WireBuzz team. Their reputation as effective customer conversion specialists through video production and marketing made it a no-brainer. Plus, we believe that the upgrading of our website in a style that emulates the top health care device companies sets the stage for Electromedical Technologies to reach that upper tier, going forward. The new site will go live later this month. In addition, we look forward to sharing new videos and testimonials with our customers, shareholders, and prospective new customers seeking an effective, non-invasive product to treat chronic pain. With over $4 million in inventory available for sale, upcoming campaigns could drive product sales as we head into 2021.”About Electromedical TechnologiesHeadquartered in Scottsdale Arizona, Electromedical Technologies, Inc. is a commercial stage, FDA cleared, bioelectronic medical device manufacturing company initially focused on the treatment of various chronic, acute, intractable, and post-operative pain conditions. Through university collaboration agreements the company is working to develop a comprehensive research program in defining the effects of electro-modulation on the human body by studying the impacts of electrical fields in cell signaling and effects on virus assembly and immune responses with the goal of improving human wellbeing. The company’s current cleared product indications are for chronic acute post traumatic and post-operative, intractable pain relief.Our animal studies do not involve any human testing, and are not related to our current products. We are conducting this research to augment and advance the science of electro-modulation in healthcare. The United States Food and Drug Administration has not reviewed or approved our animal research studiesFor more information, visit www.electromedtech.com.Safe Harbor StatementThis release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.Corporate Contact:Electromedical Technologies, Inc.
Matthew Wolfson
Tel: 1.888.880.7888
email: ceo@electromedtech.com
https://electromedtech.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.